DESTINY-Breast03 Phase 3 Study Results
Disposition and Baseline Characteristics
Dato-DXd + D
29 patients treated
5 (17%) discontinued all treatmenta
2 (7%) disease progression
2 (7%) had an adverse event
2 (7%) other
24 (83%) treatment ongoing
Median follow-up: 3.9 (range, 2-6) months
Characteristic
Age, median (range), years
No prior treatment, n (%)
Prior treatments for early-stage disease, n (%)
Radiotherapy
Cytotoxic chemotherapy
Taxane
Anthracycline
Platinum compound
Hormonal therapy
Targeted therapy
Visceral metastases, b n (%)
Lymph node metastasis, n (%)
PD-L1 expression©, n (%)
High (≥5%)
Low (<5%)
Unknown Missing
N=29
51 (33-72)
9 (31)
17 (59)
19 (66)
14 (48)
16 (55)
5 (17)
6 (21)
2 (7)
20 (69)
22 (76)
5 (17.2%)
21 (72.4%)
3 (10.3%)
Daiichi-Sankyo
Data cutoff: November 15, 2021
ESMO BC 2022 #166 Mini Oral
aPatients may have discontinued for more than 1 reason. "Defined as liver/hepatic and/or respiratory metastases. <PD-L1 expression was assessed by immunohistochemistry using the VENTANA
PD-L1 (SP263) Assay. PD-L1 expression was defined as "high" if 25% of the tumor area was populated by PD-L1 expressing tumor or immune cells, otherwise it was defined as "low".
a/mTNBC, locally advanced/metastatic triple negative breast cancer, PD-L1, programmed cell death ligand-1; TROP2, trophoblast cell-surface antigen 2.
75View entire presentation